143 related articles for article (PubMed ID: 12526176)
1. Lentiviral vectors for gene transfer to the central nervous system. Applications in lysosomal storage disease animal models.
Watson DJ; Wolfe JH
Methods Mol Med; 2003; 76():383-403. PubMed ID: 12526176
[No Abstract] [Full Text] [Related]
2. Lentiviruses as vectors for CNS diseases.
Déglon N; Aebischer P
Curr Top Microbiol Immunol; 2002; 261():191-209. PubMed ID: 11892248
[No Abstract] [Full Text] [Related]
3. From gene transfer to gene therapy in lysosomal storage diseases affecting the central nervous system.
Poenaru L
Ann Med; 2001 Feb; 33(1):28-36. PubMed ID: 11310936
[TBL] [Abstract][Full Text] [Related]
4. Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications.
Wong LF; Goodhead L; Prat C; Mitrophanous KA; Kingsman SM; Mazarakis ND
Hum Gene Ther; 2006 Jan; 17(1):1-9. PubMed ID: 16409120
[TBL] [Abstract][Full Text] [Related]
5. [Molecular pathogenesis and therapeutic targets of lysosomal diseases].
Tsuji D; Itoh K
Seikagaku; 2007 Jul; 79(7):678-82. PubMed ID: 17763701
[No Abstract] [Full Text] [Related]
6. Comparison of ventricular and intravenous lentiviral-mediated gene therapy for murine MPS VII.
Bielicki J; McIntyre C; Anson DS
Mol Genet Metab; 2010 Dec; 101(4):370-82. PubMed ID: 20864369
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy of storage disorders by retroviral and lentiviral vectors.
Biffi A; Naldini L
Hum Gene Ther; 2005 Oct; 16(10):1133-42. PubMed ID: 16218774
[No Abstract] [Full Text] [Related]
8. Cell microencapsulation: a potential tool for the treatment of neuronopathic lysosomal storage diseases.
Matte U; Lagranha VL; de Carvalho TG; Mayer FQ; Giugliani R
J Inherit Metab Dis; 2011 Oct; 34(5):983-90. PubMed ID: 21614584
[TBL] [Abstract][Full Text] [Related]
9. Development and applications of non-HIV-based lentiviral vectors in neurological disorders.
Valori CF; Ning K; Wyles M; Azzouz M
Curr Gene Ther; 2008 Dec; 8(6):406-18. PubMed ID: 19075624
[TBL] [Abstract][Full Text] [Related]
10. Intrastriatal Delivery of Integration-Deficient Lentiviral Vectors in a Rat Model of Parkinson's Disease.
Lu-Nguyen NB; Broadstock M; Yáñez-Muñoz RJ
Methods Mol Biol; 2016; 1448():175-84. PubMed ID: 27317181
[TBL] [Abstract][Full Text] [Related]
11. Central nervous system therapy for lysosomal storage disorders.
Enns GM; Huhn SL
Neurosurg Focus; 2008; 24(3-4):E12. PubMed ID: 18341388
[TBL] [Abstract][Full Text] [Related]
12. Human CD34+ hematopoietic progenitor cell-directed lentiviral-mediated gene therapy in a xenotransplantation model of lysosomal storage disease.
Hofling AA; Devine S; Vogler C; Sands MS
Mol Ther; 2004 Jun; 9(6):856-65. PubMed ID: 15194052
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy progress and prospects: gene therapy of lysosomal storage disorders.
Cheng SH; Smith AE
Gene Ther; 2003 Aug; 10(16):1275-81. PubMed ID: 12883523
[TBL] [Abstract][Full Text] [Related]
14. The trigeminal retrograde transfer pathway in the treatment of neurodegeneration.
Kyrkanides S; Yang M; Tallents RH; Miller JN; Brouxhon SM; Olschowka JA
J Neuroimmunol; 2009 Apr; 209(1-2):139-42. PubMed ID: 19278737
[TBL] [Abstract][Full Text] [Related]
15. Advanced modular self-inactivating lentiviral expression vectors for multigene interventions in mammalian cells and in vivo transduction.
Mitta B; Rimann M; Ehrengruber MU; Ehrbar M; Djonov V; Kelm J; Fussenegger M
Nucleic Acids Res; 2002 Nov; 30(21):e113. PubMed ID: 12409472
[TBL] [Abstract][Full Text] [Related]
16. Lentiviral vectors.
Jakobsson J; Ericson C; Rosenqvist N; Lundberg C
Int Rev Neurobiol; 2003; 55():111-22. PubMed ID: 12968533
[No Abstract] [Full Text] [Related]
17. Lentiviral-mediated gene therapy results in sustained expression of β-glucuronidase for up to 12 months in the gus(mps/mps) and up to 18 months in the gus(tm(L175F)Sly) mouse models of mucopolysaccharidosis type VII.
Derrick-Roberts AL; Pyragius CE; Kaidonis XM; Jackson MR; Anson DS; Byers S
Hum Gene Ther; 2014 Sep; 25(9):798-810. PubMed ID: 25003807
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietic Stem Cell Gene Therapy for Storage Disease: Current and New Indications.
Biffi A
Mol Ther; 2017 May; 25(5):1155-1162. PubMed ID: 28389320
[TBL] [Abstract][Full Text] [Related]
19. Optimized Lentiviral Transduction Protocols by Use of a Poloxamer Enhancer, Spinoculation, and scFv-Antibody Fusions to VSV-G.
Anastasov N; Höfig I; Mall S; Krackhardt AM; Thirion C
Methods Mol Biol; 2016; 1448():49-61. PubMed ID: 27317172
[TBL] [Abstract][Full Text] [Related]
20. Lentiviral-mediated gene therapy for murine mucopolysaccharidosis type IIIA.
McIntyre C; Derrick Roberts AL; Ranieri E; Clements PR; Byers S; Anson DS
Mol Genet Metab; 2008 Apr; 93(4):411-8. PubMed ID: 18248829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
